Abstract 2299P
Background
Mebendazole (Mbz), a well-known anthelminthic drug, has been demonstrated to have anti-cancer properties in tumor models and patients. The therapeutic effect of Mbz was suggested to be due to microtubule inhibition, but more recently we reported that Mbz switches macrophages from the M2 to the tumor suppressive M1 phenotype. The aims of this study were to further investigate in tumor models the cytotoxic and immunomodulatory effects of Mbz alone, in combination with cytotoxic drugs and PD-1 antibody.
Methods
Tumor samples from patients with solid or hematological malignancies undergoing diagnostic or therapeutic procedures were obtained in accordance with ethical permission. The samples were then prepared to isolated tumor cells for ex vivo testing. Ex vivo activity of Mbz alone and in combination with standard cytotoxic drugs was assessed using the fluorometric microculture cytotoxic assay. Survival index and synergy scores were calculated using GraphPad and SynergyFinder. In vivo antitumor activity of Mbz, irinotecan, a PD-1 inhibitor and their combinations were examined in a murine BALB/c model with inoculated syngeneic colon cancer cells (CT26). Tumor growth was measured by caliper and tumors were retrieved and assessed by flow cytometry for immune cell infiltration.
Results
Mbz alone showed some modest cytotoxic activity against patient tumor cells ex vivo, with hematological tumor cells being slightly more sensitive. The cytotoxic effect of Mbz was generally additive to that of other drugs but synergistic when combined with irinotecan. In the murine model, Mbz, irinotecan and the PD-1 antibody alone inhibited tumor growth. Combined with irinotecan Mbz had an additive effect, but was synergistic when combined with the PD-1 antibody. In line with the latter observation, flow cytometry showed an increase of M1 macrophages and decrease of M2 macrophages in tumors from animals treated with the combination.
Conclusions
Mbz show promising features making it suitable for repositioning into an anti-cancer drug, most notably as a modulator of the macrophage phenotype that may enhance and the effect of check-point inhibitors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sharmineh Mansoori.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2283P - Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Presenter: Benjamin Schoeps
Session: Poster session 08
2284P - Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Presenter: Andreas Ackermann
Session: Poster session 08
2285P - Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls
Presenter: Pedro Cruz
Session: Poster session 08
2286P - COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
Presenter: Ha Mo Linh Le
Session: Poster session 08
2288P - Recolony-treating solid tumors with a bacteria-based approach
Presenter: Egle Katkeviciute
Session: Poster session 08
2289P - Determining anti-cancer efficacy of a reversible LSD1 inhibitor, EXS74539, in primary AML tissues with limited thrombocytopenic effects
Presenter: Christophe Boudesco
Session: Poster session 08
2291P - WU-NK-101, best in class memory-NK cell, has key features vital for adoptive cell therapy (ACT) in solid tumors (ST)
Presenter: John Muth
Session: Poster session 08
2292P - Prevalence of druggable EGFR genomic alterations in solid tumours other than lung cancer
Presenter: Tomohiro Kondo
Session: Poster session 08
2293P - Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
Presenter: Carlotta Catozzi
Session: Poster session 08